ARIZ Precision Medicine’s goal is to destroy the driver of cancer, usually a bad protein that is produced from bad DNA inside a previously normal cell, transforming it into a cancer cell. Drivers of cancer, such as the deregulated PRDM genes and proteins, were previously thought to be “undruggable” because of the high risk of damaging normal cells. ARIZ set out to prove that by using new genetic information, nanotechnology based drug delivery systems and Nobel prize winning gene and protein altering methodologies, cancer cells could be individually and selectively targeted and destroyed. ARIZ’s proof of principle studies confirmed that this approach selectively killed multiple types of cancer cells. ARIZ is continuing to develop new drug candidates for cancer by proving that these products can destroy tumor cells in animal models of cancer. ARIZ intends to cure cancers in a way that preserves a patient’s quality of life and avoids the harmful and adverse effects of current therapies.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):